VINCOV-19, an antidote, and a cure against COVID-19, successfully completes Phase 2 Clinical Trials

VINCOV-19, developed by VINS Bioproducts in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), is the first antidote against COVID-19 and has successfully completed Phase 2 Clinical Trials across multiple centres in India.  

Hyderabad, 11 October 2022: VINS Bioproducts Limited, a leading immunological company, based in Hyderabad, in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), announced the successful completion of Phase 2 Clinical Trials of VINCOV-19, India’s first antidote and a cure against SARS-CoV-2 virus. VINCOV-19 is now ready for market authorization and for simultaneous Phase 3 Clinical Trials.

Phase 2 Clinical Trials were conducted across multiple centres in India and included over 200 patients. The Phase 2 Clinical Trials also included testing the antidote against the Omicron variant to ensure maximum coverage against the virus and its known mutations. 
Phase 2 Clinical Trials were completed successfully in September 2022. In this phase, VINCOV-19 was administered to patients with moderate severity of COVID-19. One group of patients was given VINCOV-19, along with Standard of Care (SoC), and another group was given Standard of Care (SoC) only. VINCOV-19 showed excellent safety profile in the Phase 2 Trials. There was a good and early improvement in the clinical condition of the patients administered VINCOV-19.

VINCOV-19 contains Equine polyclonal antibodies (EpAbs) against the COVID-19 virus. VINCOV-19 comprises highly purified F(ab’)2 antibody fragments that have a high neutralizing capacity against the SARS-CoV-2 virus. Since neutralizing antibodies could block the internalization of SARS-CoV-2 to lung cells, it was postulated that their passive administration should render maximal clinical benefits if they are applied at the early stages of the disease.

Dr. Vinay K. Nandicoori, Director, CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, while speaking on the successful completion of the Phase 2 Clinical Trials said, “We are very proud of the highly successful collaboration between VINS, CCMB, and UOH. These therapeutic antibodies are the first in India and among the few around the globe. It is essential to have multiple options, including therapeutic antibodies, especially for severe clinical cases of COVID. It is a major step for the future targeted collaborations between academia and industry”.

Prof. B J Rao, Vice-Chancellor, University of Hyderabad also congratulated the team members for their efforts in successfully completing Phase 2 trials for VINCOV-19. He expressed happiness at this academia and industry collaboration with complimenting technical and infrastructural strengths available in the three partnering organisations yielding fruitful results in less than a year.

Team led by Dr. Krishnan H Harshan at CCMB isolated SARS-CoV-2 in April 2020, which led to this successful collaboration. His group led the studies pertaining to the characterization of the virus, antigen, and viral neutralization assays. He said, “We are happy that we overcame all the uncertainties pertaining to the development of this product and are excited to see its success in clinical trials”.

The UoH team is headed by Dr. Nooruddin Khan, an Associate Professor at the Department of Animal Biology, School of Life sciences, University of Hyderabad. Dr. Khan specializes in the area of immunology and Vaccinology. His expertise in immunological studies helped in the success of VINCOV19 in Clinical trials. Dr. Khan said that the VINCOV19 is an outcome of outstanding academia-industry collaboration that reflects our strength in fighting pandemic.

Speaking on the successful completion of the Phase 2 Clinical Trials of VINCOV19, Siddharth Daga, Chief Executive Officer, VINS Bioproducts Limited said, “Phase 2 Clinical Trials of VINCOV-19 have been very successful. VINCOV-19 has been shown to be safe and ensures the speedy recovery of patients suffering from COVID-19. The development of VINCOV19 by VINS Bio is an affirmation of Atmanirbhar Bharat and the collaboration between the three partners is a step in the right direction. We would urge the authorities to allow us market authorization so that we can strengthen our fight against COVID-19.”
The development of VINCOV-19 is through a collaborative effort between the  Centre for Cellular and Molecular Biology (CCMB) that helped develop the viral antigen; the University of Hyderabad (UoH) that helped with product characterization; and VINS Bioproducts Limited that managed the equine immunization and clinical development in their state-of-art manufacturing plant in Telangana. 

About VINS Bioproducts Limited

VINS Bioproducts Limited, established in 1997, is a leading immunological firm, actively involved in developing life-saving antisera against snake and scorpion bites; tetanus, diphtheria, gangrene antitoxins; and rabies immunoglobulins. VINS Bioproducts Limited has 2 manufacturing facilities, spread over 12 acres, along with a 150-acre equine farm, which strictly adheres to CPCSEA norms, and an animal laboratory. Manned by experienced professionals, these facilities conform to international production standards and stringent quality controls.
VINS Bioproducts Limited is a Pharmaceutical Inspection Co-operation Scheme (PICS) approved anti-sera company which supplies its products to over 75 countries globally. It also supplies to international organizations such as the World Health Organization (WHO), the United Nations International Children’s Fund (UNICEF), the United Nations Development Programme (UNDP), and the Pan American Health Organization (PAHO). It is also recognised by the Department of Scientific and Industrial Research (DSIR) under the aegis of the Ministry of Science and Technology.